KR900018031A - 아릴술폰아미드, 이를 함유한 약제학적 조성물 및 이들의 제조방법 - Google Patents

아릴술폰아미드, 이를 함유한 약제학적 조성물 및 이들의 제조방법 Download PDF

Info

Publication number
KR900018031A
KR900018031A KR1019900006587A KR900006587A KR900018031A KR 900018031 A KR900018031 A KR 900018031A KR 1019900006587 A KR1019900006587 A KR 1019900006587A KR 900006587 A KR900006587 A KR 900006587A KR 900018031 A KR900018031 A KR 900018031A
Authority
KR
South Korea
Prior art keywords
group
compound
formula
carbon
hydrogen atom
Prior art date
Application number
KR1019900006587A
Other languages
English (en)
Other versions
KR0153527B1 (ko
Inventor
헥켈 아르민
닉클 요세프
소이카 라이너
아이제르트 볼프강
뮐러 토마스
바이젠베르거 요하네스
메아데 크리스토퍼
무아체비크 교코
Original Assignee
디터 라우딘, 게르하르트 후버
닥터 칼 토메 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE3915506A external-priority patent/DE3915506A1/de
Application filed by 디터 라우딘, 게르하르트 후버, 닥터 칼 토메 게엠베하 filed Critical 디터 라우딘, 게르하르트 후버
Publication of KR900018031A publication Critical patent/KR900018031A/ko
Application granted granted Critical
Publication of KR0153527B1 publication Critical patent/KR0153527B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

아릴술폰아미드, 이를 함유한 약제학적 조성물 및 이들의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. 일반식(I)의 아릴술폰아미드, 이들의 거울상 이성체, R4와 R5가 모두 탄소-탄소 결합을 나타내는 이들의 시스 및 트란스 이성체, 및 이들의 부가염.
  3. 상기식에서, R1은 페닐알킬, 트리알킬페닐, 테트라메틸페닐 또는 펜타메틸페닐 그룹이거나, 할로겐 원자 또는 알킬그룹에 의해 임의로 치환된 티에닐 그룹이거나, 니트로 그룹으로 1치환되거나 할로겐 원자 또는 알킬, 트리플루오로메틸 또는 알콕시 그룹으로 1 또는 2치환 될 수 있는 페닐그룹인데, 각 치환기는 같거나 상이하고, R2,R4,R5는 같거나 상이할 수 있으며 각각 수소원자 또는 알킬 그룹이며, R2는 수소원자 또는 알킬그룹이고, R4와 R5는 모두 탄소-탄소 결합이며, R3은 알킬그룹으로 임의로치환된 피리딜 그룹이고, R6는 히디록시, 알콕시, 아미노, 알킬아미노 또는 디알킬아미노 그룹이고, A는 일반식
  5. (여기서, Rn은 수소원자 또는 알킬그룹이고, R8은 수소원자이거나, R7및 R8이 모두 메틸렌 또는 에틸렌그룹이며, X는 알킬, 치환된 이미노 그룹 또는 산소 또는 황원자이며, -CHR7-그룹은 -N2R-그룹에 연결된다.)의 그룹이며, B는 탄소-탄소결합이거나 하나 또는 두개의 알킬그룹에 의해 임으로 치환된 직쇄상 C1-4알킬렌 그룹(단, 알킬 및 알콕시는 모두 탄소수가 1 내지 3개이다)이다.
  6. 제1항에 있어서, R1이 벤질, 티에닐, 클로로, 티에닐, 디클로로페닐, 디메톡시페닐, 테트라메틸페닐 또는 펜타메틸페닐 그룹이거나, 불소 또는 염소원자 또는 니트로, 메틸 또는 트리플루오로메틸 그룹에 의해 임의로 치환된 페닐 그룹이고, R2, R4및 R5는 각각 수소원자 또는 메틸 그룹이거나, R2가 수소원자 또는 메틸 그룹이고 R4와 R5가 모두 탄소-탄소 결합이며, R3가 피리딜 그룹이고, R6가 히드록시 또는 메톡시 그룹이며, A가 일반식
  8. (여기서, R7및 R8은 각각 수소원자이거나 모두가 메틸렌 또는 에틸렌 그룹이고, X는 황원자이거나 N-메틸이미노 그룹이며, -CHR7-그룹은-NR2-그룹에 연결된다.)의 그룹이고, B가 탄소-탈소 결합이거나 직쇄상 C2-4알킬렌 그룹인 일반식(I)의 아릴술폰아미드, 이들의 거울상 이성체, R4와 R5가 모두 탄소-탄소 결합을 형성하는 시스 및 트란스 이성체 및 이들의 부가염.
  9. 제1항에 있어서, R4이 테트라메틸페닐 또는 펜타메틸페닐 그룹이거나, 4-위치에서 메틸 또는 트리플루오로메틸 그룹 또는 불소, 염소 또는 브롬원자로 치환된 페닐 그룹이고, R2,R4, 및 R5가 각각 수소원자이거나, R2가 수소원자이고 R4와 R5가 모두 탄소-탄소 결합이며, R3가 3-피리딜 그룹이고, A가 일반식(여기서, R7및 R5은 각각 수소원자이거나 R7와 R8이 모두 메틸렌 그룹이다.)의 그룹이며, R6가 히드록시 그룹인 일반식(I)의 아릴술폰아미드, 이들의 거울상 이성체, R4와 R5가 모두 탄소-탄소 결합을 형성하는 이들의 시스 및 트란스 이성체, 및 이들의 부가염.
  10. 제1항에 있어서, 6-(2-4-톨루엔술포닐아미노)인단-5-일)-6-(3-피리닐)헥스-5-엔오산, 6-(4(2-4-클로로벤젠술포닐아미노)에틸)에틸)페닐)-6-(3-피리닐)헥스-5-엔오산 및 6-(4-(2-4-트리플루오로메틸벤젠술포닐아미노)에틸)페닐)-6-(3-피리딜)헥스-5-엔오산인 일반식(I)의 화합물, 및 이들의 산부가염.
  11. 6-(4(2-4-클로로벤젠술포닐아미노)에틸)페닐)-6-(3-피리닐)헥스-5-엔오산 및 이의 산부가염
  12. 제1항 내지 제5항중 어느 한 항에 따른 화합물의 생리학적으로 허용되는 무기염기 또는 유기염화와의 부가염.
  13. 제1항 내지 제5항중 어느 한 항에 따른 화합물 또는 제6항에 따른 이들 화합물의 생리학적으로 허용되는 부가염을 활성물질로 함유하고 임의로 비활성 담체 및/또는 희석제 한가지 이상을 함께 항뮤하는 약제학적 조성물.
  14. 제7항에 있어서, 혈전전색증 치료 및 예방, 동맥경화증과 혼합감염 예방 및 국소성 빈혈, 천식 및 알레르기, 치료에 적합한 약제학적 조성물.
  15. 제7항에 있어서, 모세혈관의 트롬복산에 의한 수축 또는 PGE2에 의한 팽창과 관련한 여러가지 질환에 있어서 이식거부 반응을 감소시키고, 시클로로스포린 같은 물질의 신장 독성을 감소시키며 신장 질환을 치료하고 충격상태를 치료하는데 적합한 약제학적 조성물.
  16. 제7항 내지 제9항중 어느 한 항에 있어서, PDE억제제 또는 용해제를 활성 물질로서 추가로 함유함을 특징으로 하는 약제학적 조성물.
  17. 제1항 내지 제5항중 어느 한 항에 따른 화합물 또는 제6항에 따른 이들 화합물의 생리학적으로 허용되는 부가염을 임으로 PDE 억제제 또는 용해제와 더불어 종래의 비활성 담체 및/또는 희석제중에 비화학적인 방법으로 혼입함을 특징으로 하는 제7항 내지 제10항중 어느 한 항에 따른 약제학적 조성물의 제조방법.
  18. (a)일반식(Ⅱ)의 화합물을 일반식(Ⅲ)의 술폰산 유도체로 아실화하거나, (b)R6가 히드록시 그룹인 일반식(I)의 화합물을 제조하기위해 일반식(Ⅳ)의 화합물로부터 보호기를 제거하거나, (c)R4및 R5가 각각 수소원자인 일반식(I)의 화합물은 제조하기 위해 일반식(Ⅴ)의 화합물은 수소화시키거나, (d)R4및 R5가 모두 탄소-탄소 결합인 일반식(I)의 화합물을 제조하기 위해 일반식(Ⅵ)의 화합물을 일반식(Ⅶ)의 화합물과 반응시킨 다음 임의로 탈수시키고, 필요한 경우 R2가 수소원자인 수득한 일반식(I)의 화합물을 알킬화하여 R2가 알킬 그룹인 일반식(I)의 상응하는 화합물로 전화시키거나, R6가 히드록시그룹인, 수득한 일반식(I)의 화합물을 에스테르화하거나 아미드화하여 R6가 알콕시, 아미노, 알킬아미노 또는 디알킬아미노그룹인 일반식(I)의 상응한 화합물로 전환시킬 수 있거나, R4및 R5가 모두 탄소-탄소 결합인 일반식(I)의 화합물을 분할하여 그의 시스-또는 트란스-이성체를 수득하거나, 수득한 일반식(I)의 화합물을 분할하여 그의 거울상 이성체를 수득하거나, 수득한 일반식(I)의 화합물을 그의 부가염 특히 유기 염기 또는 무기 염기와의 생리학적으로 허용되는 부가염으로 전환시킴을 특징으로 하여 제1항 내지 제6항중 어느 한 항에 따른 화합물을 제조하는 방법.
  20. 상기식에서 R1내지 R6, A 및 B는 제1항 내지 제5항중 어느 한 항에 있어서 정의된 바와 같고, X는 염소 또는 브롬원자와 같은 할로겐원자 또는 메톡시 또는 에톡시 등과같은 알콕시그룹등의 친핵성 이탈기이며, Z는 가수분해, 염분해 또는 가수분해에 의해 쉽게 제거되는 카르복시그룹의 보호기이거나 카르복시그룹의 기능성 유도체이고, R5'는 수소원자 또는 C1-3알킬그룹이며, W는 트리페닐포스포늄 할라이드, 디알킬포스폰산 또는 마그네슘 할라이드 그룹이다.
  21. ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900006587A 1989-05-12 1990-05-10 아릴설폰아미드 및 이를 함유하는 약제학적 조성물 KR0153527B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE3915506A DE3915506A1 (de) 1989-05-12 1989-05-12 Neue arylsulfonamide, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DEP3915506.4 1989-05-12
DEP39155064 1989-05-12
DE3932403A DE3932403A1 (de) 1989-05-12 1989-09-28 Neue arylsulfonamide, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DEP3932403.6 1989-09-28

Publications (2)

Publication Number Publication Date
KR900018031A true KR900018031A (ko) 1990-12-20
KR0153527B1 KR0153527B1 (ko) 1998-11-16

Family

ID=25880794

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900006587A KR0153527B1 (ko) 1989-05-12 1990-05-10 아릴설폰아미드 및 이를 함유하는 약제학적 조성물

Country Status (21)

Country Link
US (3) US5294626A (ko)
EP (1) EP0397044B1 (ko)
JP (1) JP2868283B2 (ko)
KR (1) KR0153527B1 (ko)
AT (1) ATE132138T1 (ko)
AU (1) AU627024B2 (ko)
CA (1) CA2016646C (ko)
DE (2) DE3932403A1 (ko)
DK (1) DK0397044T3 (ko)
ES (1) ES2083394T3 (ko)
FI (1) FI95372C (ko)
GR (1) GR3019044T3 (ko)
HU (1) HU214586B (ko)
IE (1) IE74207B1 (ko)
IL (1) IL94347A0 (ko)
MX (1) MX9202816A (ko)
NO (1) NO176176C (ko)
NZ (1) NZ233638A (ko)
PT (1) PT93994B (ko)
RU (1) RU2096405C1 (ko)
UA (1) UA26136C2 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153214A (en) * 1989-06-28 1992-10-06 Ciba-Geigy Corporation Certain (arylsulfonamido- and imidazolyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity
DE4025818A1 (de) * 1990-08-16 1992-02-20 Bayer Ag Phenylsulfonamid substituierte pyridinalken- und -aminooxyalkancarbonsaeure-derivate
US5286736A (en) * 1990-11-22 1994-02-15 Dr. Karl Thomae Gmbh Pyridyl compounds and pharmaceutical compositions containing these compounds
DE4037112A1 (de) * 1990-11-22 1992-05-27 Thomae Gmbh Dr K Neue pyridylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5374641A (en) * 1991-02-25 1994-12-20 Terumo Kabushiki Kaisha N-(3-pyridylalkyl)sulfonamide compounds which have useful pharmaceutical activity
GB9107043D0 (en) * 1991-04-04 1991-05-22 Pfizer Ltd Therapeutic agents
DE4216364A1 (de) * 1991-12-14 1993-11-25 Thomae Gmbh Dr K Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2686339B1 (fr) * 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DE4213919A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE69823240T2 (de) * 1998-10-23 2005-04-28 Toray Industries, Inc. Immunmodulierende arzneimittelzusammenstellung
CA2758105A1 (en) 2009-04-09 2010-10-14 N.V. Organon Indane derivatives
ES2525748T3 (es) 2009-11-13 2014-12-29 Toray Industries, Inc. Agente terapéutico o profiláctico para la diabetes
US9955802B2 (en) 2015-04-08 2018-05-01 Fasteners For Retail, Inc. Divider with selectively securable track assembly

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1134828A (en) * 1978-12-28 1982-11-02 Tadao Tanouchi Pyridine derivatives
DE3373467D1 (en) * 1982-06-14 1987-10-15 Takeda Chemical Industries Ltd Vinyl carboxylic acid derivatives, their production and use
US4518602A (en) * 1982-10-07 1985-05-21 Takeda Chemical Industries, Ltd. Vinyl carboxylic acid derivatives, their production and use as inhibitors of thromboxane synthetase
US4563446A (en) * 1983-07-27 1986-01-07 Takeda Chemical Industries, Ltd. Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines
DE3689506D1 (de) * 1985-10-09 1994-02-17 Shell Int Research Neue Acrylsäureamide.
DE3623944A1 (de) * 1986-07-16 1988-02-11 Thomae Gmbh Dr K Neue benzolsulfonamido-indanylverbindungen, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB8708233D0 (en) * 1987-04-07 1987-05-13 Smith Kline French Lab Pharmaceutically active compounds
EP0304271A3 (en) * 1987-08-20 1992-09-02 Smith Kline & French Laboratories Limited Omega-arylsulphonamidoalkanoic acids for treatment of thromboxane medited diseases

Also Published As

Publication number Publication date
IE74207B1 (en) 1997-07-16
ES2083394T3 (es) 1996-04-16
IE901708A1 (en) 1991-06-19
RU2096405C1 (ru) 1997-11-20
AU5492490A (en) 1990-11-15
GR3019044T3 (en) 1996-05-31
FI902358A0 (fi) 1990-05-11
CA2016646A1 (en) 1990-11-12
NO902099L (no) 1990-11-13
ATE132138T1 (de) 1996-01-15
CA2016646C (en) 1999-09-07
DK0397044T3 (da) 1996-05-13
NZ233638A (en) 1992-03-26
NO176176B (no) 1994-11-07
JP2868283B2 (ja) 1999-03-10
FI95372C (fi) 1996-01-25
IL94347A0 (en) 1991-03-10
US5426119A (en) 1995-06-20
US5294626A (en) 1994-03-15
DE59009994D1 (de) 1996-02-08
PT93994B (pt) 1997-04-30
US5681961A (en) 1997-10-28
NO902099D0 (no) 1990-05-11
IE901708L (en) 1990-11-12
EP0397044A3 (de) 1991-10-16
HUT54649A (en) 1991-03-28
UA26136C2 (uk) 1999-06-07
KR0153527B1 (ko) 1998-11-16
PT93994A (pt) 1991-01-08
HU903013D0 (en) 1990-09-28
EP0397044B1 (de) 1995-12-27
NO176176C (no) 1995-02-15
HU214586B (hu) 1998-04-28
FI95372B (fi) 1995-10-13
MX9202816A (es) 1992-06-30
JPH035457A (ja) 1991-01-11
AU627024B2 (en) 1992-08-13
EP0397044A2 (de) 1990-11-14
DE3932403A1 (de) 1991-04-11

Similar Documents

Publication Publication Date Title
KR900018031A (ko) 아릴술폰아미드, 이를 함유한 약제학적 조성물 및 이들의 제조방법
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
JP3545416B2 (ja) フペルジンａ誘導体、その製造およびその使用
RU2006101890A (ru) Производные тиазолилпиперидина в качестве ингибиторов мпб
DE60226912D1 (de) Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
EA200600358A1 (ru) Фенил- или пиридиламидные соединения в качестве антагонистов простагландина е2
DE69923300D1 (de) Cycloalken-derivate, verfahren zu ihrer herstellung und ihre verwendung
DK1694641T3 (da) Prostaglandinsyntese
EA200200611A1 (ru) Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции
DE3851999D1 (de) Verfahren zur Herstellung von Sulfonylharnstoff-Derivaten.
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
DE69725167D1 (de) N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
ATE187721T1 (de) (3s, 4s)-delta-6-tetrahydrocannabinol-7-säuren und ihre derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
KR900009670A (ko) 혈소판 활성인자의 길항질인 신규 비스-아릴포스페이트 에스테르 및 그의 제조방법 및 그로써 질병을 치료하는 방법
KR920021537A (ko) 벤조피란 유도체와 그의 제조 방법(ii)
EP0624582A1 (fr) Benzodioxines substituées, leur procédé de préparation et les compositions pharmaceutiques les contenant
EA200500032A1 (ru) Производные ацилоксипирролидина и их применение в качестве лигандов v1b или v1b и v1a рецепторов
KR920009799A (ko) 피리딜 유도체, 이를 함유하는 약제학적 조성물 및 이의 제조방법
KR910004632A (ko) 신규한 1-옥사-2-옥소-8-아자스피로[4,5]데칸 유도체와 그들을 포함하는 약제학적 조성물 및 그 제조방법
NO20016366D0 (no) Mellomprodukter for syntese av benzimidazolforbindelser, og fremgangsmåte for fremstilling derav
DE602004020050D1 (de) Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte
CO5280074A1 (es) Nuevos compuestos de piperidina-4,2 (1 h)-quinazolina, composiciones farmaceuticas que las contienen y proceso para su preparacion
NO20021162L (no) 5-aminoalkyl og 5-aminokarbonyl-substituerte indoler
AU647704B2 (en) 1,2,3,6-tetrahydropyridine derivatives useful for improving cerebal blood circulation

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee